Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net loss	$ (5,229,725)	$ (26,671,857)	$ (12,826,409)
Depreciation	512,366	389,439	357,568
Amortization	13,147	17,850	4,575
Noncash compensation	4,044,858	6,662,130	3,730,646
Warrant issuance costs	150,827	231,980	266,970
Change in value of warrant liability	(19,821,787)	16,011,769	6,267,665
Patent costs	1,481,318		35,564
Changes in operating assets and liabilities:
Accounts receivable	3,641,491	(1,990,774)	(2,347,526)
Other current assets	123,197	(611,885)	139,165
Other long-term assets	(919)	(8,656)
Accounts payable	(348,282)	53,370	106,672
Deferred revenue	(2,317,218)	(12,398)	(35,696)
Accrued expenses	1,088,556	(35,109)	(208,279)
Accrued bonuses	(243,219)	64,810	264,141
Net cash used in operating activities	(16,905,390)	(5,899,331)	(4,244,944)
Cash flows from investing activities:
Purchase of short-term investments	(5,520,000)	(459,364)
Sale of short-term investments	434,835		1,000,000
Purchase of equipment	(655,553)	(465,650)	(136,400)
Investment in patents	(326,171)	(250,735)	(237,064)
Net cash provided by (used in) investing activities	(6,066,889)	(1,175,749)	626,536
Cash flows from financing activities:
Net proceeds from issuance of preferred stock			4,441,162
Net proceeds from issuance of common stock	21,946,801	12,234,693
Preferred stock dividends			(936,644)
Exercise of options	532,408	901,911	362,857
Exercise of warrants	949,793	418,926	414,284
Net cash provided by financing activities	34,769,442	17,065,094	4,281,659
Effect of exchange rate change on cash and equivalents	156,889	(34,577)
Increase in cash and cash equivalents	11,954,052	9,955,437	663,251
Cash and cash equivalents at beginning of year	10,918,537	963,100	299,849
Cash and cash equivalents at end of year	22,872,589	10,918,537	963,100
Supplemental schedule of noncash financing activities:
Conversion of warrant liability to equity upon warrant exercise	995,428	2,020,031	874,120
Financing Costs [Member]
Supplemental schedule of noncash financing activities:
Noncash financing costs on common stock offering	207,905	227,486
Noncash warrant issuance costs	207,905	227,486
Warrant Issue Costs [Member]
Supplemental schedule of noncash financing activities:
Noncash financing costs on common stock offering	19,361	91,283
Noncash warrant issuance costs	19,361	91,283
Incuron LLC [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution to Incuron, LLC	2,340,374	3,509,564
Noncontrolling interest capital contribution to Panacela Labs, Inc.	2,340,374	3,509,564
Panacela Labs Inc [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution to Incuron, LLC	9,000,066
Noncontrolling interest capital contribution to Panacela Labs, Inc.	$ 9,000,066